HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer

November 19th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Dr. Borgen on Successful Progress in HER2-Positive Breast Cancer

November 17th 2016

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses the successful progress seen in the treatment landscape of HER2-positive breast cancer.

Improved Patient Selection Needed to Advance HER2+ Breast Cancer Care

November 17th 2016

Immunotherapy and chemotherapy are options physicians should not dismiss for patients with HER2-positive breast cancer, according to Lisa Carey, MD, even with the available targeted agents trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine.

Dr. Tripathy on Neoadjuvant Agents for HER2+ Breast Cancer

November 16th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.

Expert Sheds Light on Efficacy of Dual HER2-Directed Therapy

November 15th 2016

Dual HER2-directed therapy has demonstrated promising efficacy as a treatment approach for patients with breast cancer. Still, there remains a need for further research pertaining to therapies for HER2-positive patients who do do not meet the current criteria for this neoadjuvant regimen.

Dr. Anders on Systemic Agents for Patients With Breast Cancer and Brain Mets

November 15th 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.

Large Gene Network Required to Predict Response to HER2-Targeted Therapy

November 2nd 2016

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Dr. Blackwell on the Impact of the CLEOPATRA and MARIANNE Studies in HER2+ Breast Cancer

November 1st 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the lasting impact that the CLEOPATRA and MARIANNE studies have had on the treatment landscape in HER2-positive breast cancer.

Pegram Excited for Additional Advances in HER2+ Breast Cancer

October 25th 2016

Mark Pegram, MD, sheds light on some of the recent groundbreaking trials in HER2-positive breast cancer and how they have come to shape the current treatment paradigm.

Blackwell Hopeful New Agents Will Advance HER2+ Breast Cancer Care

October 25th 2016

Kimberly L. Blackwell, MD, discusses the latest advances for patients with HER2-positive breast cancer and provides insight on the hurdles that still remain.

Dr. Carey on Possibility of Immunotherapy in HER2+ Breast Cancer

October 22nd 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the possibility of administering immunotherapy as treatment for patients with HER2-positive breast cancer.

Novel HER2-Targeting Antibody-Drug Conjugate Shows Broad Antitumor Activity

October 20th 2016

A novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Dr. Blackwell on Treatment Landscape of HER2+ Breast Cancer

October 19th 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the available treatments for patients with HER2-positive breast cancer, as well as other agents that are in development.

Dr. Sanft on Treatment Options in HER2-Positive Breast Cancer

October 18th 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.

Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer

October 14th 2016

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.

Dr. Verma on Treatments in the Neoadjuvant Setting of HER2-Positive Breast Cancer

October 13th 2016

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses the overall treatment paradigm in the neoadjuvant setting of HER2-positive breast cancer.

Dr. Burris on Remaining Challenges in Treating HER2+ Breast Cancer

October 7th 2016

Howard A. “Skip” Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, a 2014 Giant of Cancer Care in Drug Development, discusses the biggest remaining challenges in treating patients with HER2-positive breast cancer.

Dr. Hamilton on Research Needed in HER2-Positive Breast Cancer

October 6th 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

Expert Discusses Latest Data in Neoadjuvant HER2+ Breast Cancer

September 27th 2016

Stephen K. Chia, MD, highlights the key findings from the KRISTINE and NSABP B-41 trials and their implications for the treatment of HER2-positive breast cancer.

Expert Sheds Light on Issues With ASCO-CAP HER2 Guidelines

September 27th 2016

Michael F. Press, MD, PhD, discusses a retrospective study comparing the original FDA-approved criteria for HER2 gene amplification in breast cancer with the current ASCO-CAP guidelines, and exactly how the 2 sets of guidelines differ from one another.